BioWorld Asia

Feb. 20, 2002

Microscience Completes £25.5M Round, Plans Clinical Programs

LONDON - Microscience Ltd. raised £25.5 million (US$36.3 million) in a third-round funding, enabling it to put five infectious disease vaccines into clinical trials this year and develop them through to Phase IIb. (BioWorld International) Read More

Hungarian Firm ComGenex Adds Discovery To Chemistry Services

Common Gene Links Immune System’s Generation Of Diversity

British Biotech Gains License To Cancer Drug In Phase II

Alizyme Receives Approval For Phase III Trial Of Colal-Pred

LION Streamlining Operations, Eliminating About 80 Positions

EU Commissioner Continues Push For Changes In Policy

HiberGen Raises EUR3.8M In Follow-On Funding From Trinity

Other News To Note

Oxagen, Insmed Enter Alliance On Polycystic Ovary Syndrome

Arrow Raises £7M In Second Round For Anti-Infectives Work

Australian Researchers Isolate Gene Implicated In Hay Fever

Sanofi-Synthélabo Selects Melanoma Vaccine From IDM

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...